AMERICAN JOURNAL OF HEMATOLOGY

Scope & Guideline

Elevating Knowledge in Blood Health and Treatment

Introduction

Welcome to the AMERICAN JOURNAL OF HEMATOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of AMERICAN JOURNAL OF HEMATOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0361-8609
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1976 to 2024
AbbreviationAM J HEMATOL / Am. J. Hematol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The American Journal of Hematology focuses on advancing the understanding and treatment of blood disorders through rigorous research and clinical studies. Its scope encompasses a wide range of hematological conditions and therapeutic approaches, with a commitment to disseminating findings that have a significant impact on patient care and outcomes.
  1. Hematological Malignancies:
    The journal extensively covers research on leukemia, lymphoma, and myeloma, focusing on novel therapies, clinical trials, and molecular genetics that influence treatment and prognosis.
  2. Transfusion Medicine:
    Research related to transfusion practices, blood safety, and the management of transfusion-related complications is a key area, reflecting the journal's commitment to improving patient care in transfusion settings.
  3. Sickle Cell Disease and Thalassemia:
    Papers often explore the pathophysiology, management strategies, and innovative therapies for sickle cell disease and thalassemia, aiming to improve health outcomes for affected individuals.
  4. Coagulation Disorders:
    The journal includes research on various coagulation disorders, including hemophilia and thrombosis, focusing on new treatment modalities and strategies for management.
  5. Stem Cell Transplantation:
    There is a significant emphasis on studies related to hematopoietic stem cell transplantation, including donor selection, conditioning regimens, and post-transplant outcomes.
  6. Clinical Trials and Therapeutics:
    The journal publishes findings from clinical trials of new drugs, treatment regimens, and innovative therapies, contributing to the evidence base for clinical practice.
The American Journal of Hematology has seen a rise in interest in several emerging themes and trends that reflect the evolving landscape of hematological research and patient care. These include advancements in technology and novel therapeutic approaches.
  1. Immunotherapy and CAR-T Cell Therapy:
    There is a growing emphasis on the development and application of immunotherapies, particularly CAR-T cell therapies, for hematological malignancies, showcasing innovative treatment options.
  2. Targeted Therapy and Precision Medicine:
    Research focusing on targeted therapies based on genetic and molecular profiling of hematological disorders is on the rise, reflecting a shift towards personalized treatment approaches.
  3. Biomarkers and Minimal Residual Disease Monitoring:
    Emerging studies are increasingly focusing on the identification and utilization of biomarkers for disease monitoring and prognosis, particularly in acute myeloid leukemia and other malignancies.
  4. Health Disparities and Patient-Centered Care:
    The journal is increasingly addressing health disparities within hematology, emphasizing the importance of equitable care and patient-reported outcomes in treatment strategies.
  5. Long-term Effects of COVID-19 on Hematology Patients:
    Research exploring the implications of COVID-19 on patients with existing hematological conditions, including vaccine responses and management challenges, has gained prominence.
  6. Artificial Intelligence and Machine Learning in Hematology:
    There is a notable trend towards integrating artificial intelligence and machine learning into hematology research, particularly in diagnostics and treatment personalization.

Declining or Waning

While the American Journal of Hematology continues to be a leading publication in the field, certain topics have seen a decline in focus over recent years. This may reflect shifts in research priorities or advancements in understanding that have lessened the need for certain types of studies.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in studies focusing solely on traditional chemotherapy regimens as the field moves towards targeted therapies and immunotherapies, which are now the focus of many clinical trials.
  2. Basic Science Research:
    The journal has shifted towards more clinically relevant studies, with a waning interest in purely basic science research that does not directly translate to clinical applications.
  3. Epidemiological Studies:
    Although still important, there appears to be a reduction in the volume of studies that solely focus on the epidemiology of hematological disorders, as the emphasis shifts towards treatment outcomes and therapeutic innovations.
  4. Longitudinal Studies in Hematology:
    Fewer longitudinal studies are being published, as funding and interest may be shifting towards more immediate, impactful clinical trials and translational research.

Similar Journals

HemaSphere

Transforming knowledge into patient care advancements.
Publisher: WILEYISSN: Frequency: 12 issues/year

HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.

Blood Cancer Journal

Leading the charge in hematology and oncology.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Pioneering discoveries in transfusion medicine since 1973.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

VOX SANGUINIS

Exploring the Frontiers of Blood Medicine
Publisher: WILEYISSN: 0042-9007Frequency: 12 issues/year

VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.

Therapeutic Advances in Hematology

Transforming research into impactful therapies.
Publisher: SAGE PUBLICATIONS LTDISSN: 2040-6207Frequency: 1 issue/year

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

ANNALS OF HEMATOLOGY

Advancing hematological science through rigorous research.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

EUROPEAN JOURNAL OF HAEMATOLOGY

Innovative Insights into Blood Health and Disease
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Asian Journal of Transfusion Science

Empowering research in hematology and immunology.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0973-6247Frequency: 2 issues/year

Asian Journal of Transfusion Science, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, is a prominent open-access journal dedicated to the interdisciplinary fields of hematology and immunology. With an ISSN of 0973-6247 and E-ISSN 1998-3565, it serves as a crucial platform for researchers, clinicians, and students from around the globe, facilitating the dissemination of high-quality, peer-reviewed research. Established in 2007, the journal has consistently aimed to advance scientific knowledge in transfusion practices, enhancing patient care and safety in transfusion medicine. Despite its recent categorization in the Q4 quartile within both Hematology and Immunology, the journal is making strides toward greater visibility in the academic community, with plans for expanded reach and increased citation impact. With its commitment to open-access publishing, the Asian Journal of Transfusion Science ensures that invaluable research findings are readily accessible to all stakeholders, thereby bolstering collaborative efforts in transfusion science and related disciplines.

Blood Transfusion

Enhancing Lives Through Blood Transfusion Innovations.
Publisher: SIMTIPRO SRLISSN: 1723-2007Frequency: 6 issues/year

Blood Transfusion is a leading journal in the fields of Hematology, Immunology, and Medicine, published by SIMTIPRO SRL in Italy. With its ISSN 1723-2007, the journal has established a significant presence in the academic community, as evidenced by its positioning within the Q2 category in Hematology and Medicine (miscellaneous) and Q3 in Immunology and Allergy for 2023. Notably, it ranks #38 out of 137 in the Hematology category, showcasing its impactful contributions to research and practice. Operating under a traditional publishing model, this journal provides valuable insights into advances in blood transfusion science, ultimately aimed at enhancing patient care and outcomes. Spanning from 2003 to 2024, the scope of Blood Transfusion covers a wide range of topics related to hematological and immunological research, making it an essential resource for researchers, healthcare professionals, and students engaged in these critical fields.

Iraqi Journal of Hematology

Connecting Global Scholars in Blood Science
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2072-8069Frequency: 2 issues/year

Iraqi Journal of Hematology is a prominent peer-reviewed open-access journal dedicated to advancing the field of hematology. Published by Wolters Kluwer Medknow Publications, this journal provides a platform for researchers, professionals, and students to share cutting-edge findings and developments in various aspects of hematology, including blood diseases, diagnostics, and innovative treatments. Since its transition to open access in 2016, the journal has significantly increased its reach, allowing for wider dissemination of critical research to a global audience. With an ISSN of 2072-8069 and an E-ISSN of 2543-2702, the Iraqi Journal of Hematology strives to adhere to the highest scholarly standards and plays a vital role in the ongoing discourse in hematological research. Researchers are encouraged to contribute to this essential resource for the scientific community, contributing to the advancement of knowledge that ultimately improves patient care and treatment outcomes.